Research programme: neuropeptide FF receptor antagonists - Merck
Latest Information Update: 30 Aug 2011
At a glance
- Originator Merck AG
- Mechanism of Action Neuropeptide FF receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 30 Aug 2011 No development reported for Obesity in USA (unspecified route)
- 19 Nov 2008 Early research in Obesity in USA (unspecified route)